当前位置: X-MOL 学术Mini-Rev. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria
Mini-Reviews in Medicinal Chemistry ( IF 3.3 ) Pub Date : 2020-10-31 , DOI: 10.2174/1389557520666200818211405
Manaf AlMatar 1 , Osman Albarri 2 , Essam A. Makky 1 , Işıl Var 3 , Fatih Köksal 4
Affiliation  

The need for new therapeutics and drug delivery systems has become necessary owing to the public health concern associated with the emergence of multidrug-resistant microorganisms. Among the newly discovered therapeutic agents is cefiderocol, which was discovered by Shionogi Company, Japan as an injectable siderophore cephalosporin. Just like the other β-lactam antibiotics, cefiderocol exhibits antibacterial activity via cell wall synthesis inhibition, especially in Gram negative bacteria (GNB); it binds to the penicillin-binding proteins, but its unique attribute is that it crosses the periplasmic space of bacteria owing to its siderophore-like attribute; it also resists the activity of β-lactamases. Among all the synthesized compounds with the modified C-7 side chain, cefiderocol (3) presented the best and well-balanced activity against multi-drug resistant (MDR) Gram negative bacteria, including those that are resistant to carbapenem. İn this article, an overview of the recent studies on cefiderocol was presented.



中文翻译:

头孢地洛尔对敏感和耐多药(MDR)细菌的活性概述

由于与多药耐药微生物的出现有关的公共卫生问题,对新疗法和药物输送系统的需求已变得必要。在新发现的治疗剂中有头孢地洛尔,它是由日本盐之木公司发现的一种可注射的铁载体头孢菌素。与其他β-内酰胺类抗生素一样,头孢地洛尔通过抑制细胞壁合成表现出抗菌活性,尤其是在革兰氏阴性细菌(GNB)中。它与青霉素结合蛋白结合,但其独特的特性是由于其铁载体样特性而穿过细菌的周质空间。它也抵抗β-内酰胺酶的活性。在所有具有修饰的C-7侧链的合成化合物中,头孢地洛尔(3)对多重耐药(MDR)革兰氏阴性细菌,包括对碳青霉烯耐药的细菌,表现出最佳且均衡的活性。在本文中,对头孢地洛尔的最新研究进行了概述。

更新日期:2020-12-07
down
wechat
bug